Trial name/Author Year Study design Number of patients Product Route of administration Follow-up duration Outcomes Total Treated Control Kim et al. [74] 2006 Patient series 4 4 0 HLA matched UCB-derived MSCs SC or IM 4 months Rest pain ↑swithin 14 days, Wound healing ↑uwithin 120 days, Angiographic collateral vessels ↑ Dash et al. [75] 2009 RCT 24 12 12 BM-MSCs IM 12 weeks Pain-free walking distance ↑, Ulcer size ↓ Lu et al. [77] 2011 RCT double- blind 41 (82 limbs) 41 limbs 41limbs BM-MSCs (20 limbs) BM-MNCs (21 limbs) IM 24 weeks BM-MSCs vs Control ABPI ↑, TcPO2 ↑, Rest pain scale ↓, Pain-free walking time ↑, Angiographic score ↑, Ulcer healing ↑ BM-MSC vs BM-MNCs ABPI ↑, TcPO2 ↑, Rest pain scale ↓, Pain-free walking time ↑, Angiographic score ↑, Ulcer healing ↑, Rest pain scale →, Amputation rate → Lasala et al. [108] 2010 Patient series 10 10 0 BM-MSCs +BM-MNCs IM 10 months Total walking time ↑, ABPI ↑, QOL ↑ Lasala et al. [76] 2012 Patient series 26 26 limbs 26 limbs BM-MSCs +BM-MNCs IM 4 months ABPI ↑, Total walking time ↑, QOL ↑, Scintigraphic limb perfusion ↑ RESTORE-CLI Powell et al. [79] 2011 RCT 46 32 14 Ixmyelocel-T IM 6 months 12 months Amputation-free suivival ↑ Ulcer healing ↑ ACellDREAM Bura et al. [88] 2014 Patient series 7 7 0 ADSCs IM 6 months TcPO2 ↑ Ulcer healing ↑ ADSC indicates adipose-derived stem cell; HLA, human leukocyte antigen; MSC, mesenchymal stem cell; SC, subcutaneous; UCB, umbilical cord blood.

Table 5: Clinical trials of MSCs for CLI.